Canaccord Genuity Maintains Buy on Twist Bioscience, Lowers Price Target to $150
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Canaccord Genuity analyst Kyle Mikson maintains Twist Bioscience (NASDAQ:TWST) with a Buy and lowers the price target from $205 to $150.
Canaccord Genuity analyst Kyle Mikson maintains Twist Bioscience (NASDAQ:TWST) with a Buy and lowers the price target from $205 to $150.
